Skip to Main Content
S. Karger AG
header search
Search
Advanced Search
Skip Nav Destination

Rifaximin: In vitro and in vivo Antibacterial Activity – A Review

Chemotherapy (2005) 51 (Suppl. 1): 67–72.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
Machine Learning-Assisted High-Throughput Screening for Anti-MRSA Compounds
  • Fadi Shehadeh
  • LewisOscar Felix
  • Markos Kalligeros
  • Adnan Shehadeh
  • Beth Burgwyn Fuchs
  • Frederick M. Ausubel
  • Paul P. Sotiriadis
  • Eleftherios Mylonakis
IEEE/ACM Transactions on Computational Biology and Bioinformatics (2024) 21 (6): 1911.
Rifaximin and alternative agents in the management of irritable bowel syndrome: A comprehensive review
  • Aylin Deljavan Ghodrati
  • Tansel Comoglu
Archiv der Pharmazie (2024) 357 (10)
Drug Polymorphism: An Important Pre-formulation Tool in the Formulation Development of a Dosage Form
  • Prateek Singh
  • Shaweta Sharma
  • Pramod Kumar Sharma
  • Aftab Alam
Current Physical Chemistry (2024) 14 (1): 2.
Inhibition of urease-mediated ammonia production by 2-octynohydroxamic acid in hepatic encephalopathy
  • Diana Evstafeva
  • Filip Ilievski
  • Yinyin Bao
  • Zhi Luo
  • Boris Abramovic
  • Sunghyun Kang
  • Christian Steuer
  • Elita Montanari
  • Tommaso Casalini
  • Dunja Simicic
  • Dario Sessa
  • Stefanita-Octavian Mitrea
  • Katarzyna Pierzchala
  • Cristina Cudalbu
  • Chelsie E. Armbruster
  • Jean-Christophe Leroux
Nature Communications (2024) 15 (1)
Advances in Therapy for Irritable Bowel Syndrome with Diarrhea: Role of Rifaximin in Combination with Metronidazole
  • Arif A. Faruqui
Journal of Medical Sciences (2024) 44 (1): 1.
Therapeutic potential of rifaximin in liver diseases
  • Wanting Yang
  • Gaoyue Guo
  • Chao Sun
Biomedicine & Pharmacotherapy (2024) 178: 117283.
The potential for development of clinically relevant microbial resistance to rifaximin-α: a narrative review
  • Herbert L. DuPont
  • Graeme N. Forrest
Clinical Microbiology Reviews (2023) 36 (4)
Dosing of Rifaximin Soluble Solid Dispersion Tablets in Adults With Cirrhosis: 2 Randomized, Placebo-controlled Trials
  • Jasmohan S. Bajaj
  • Tarek I. Hassanein
  • Nikolaos T. Pyrsopoulos
  • Arun J. Sanyal
  • Robert S. Rahimi
  • Zeev Heimanson
  • Robert J. Israel
  • Don C. Rockey
Clinical Gastroenterology and Hepatology (2023) 21 (3): 723.
The pathogenesis of gut microbiota in hepatic encephalopathy by the gut–liver–brain axis
  • Ruirui Zhu
  • Liwen Liu
  • Guizhen Zhang
  • Jianxia Dong
  • Zhigang Ren
  • Zhiqin Li
Bioscience Reports (2023) 43 (6)
An Overview of Short-Bowel Syndrome in Pediatric Patients: Focus on Clinical Management and Prevention of Complications
  • Chiara Caporilli
  • Giuliana Giannì
  • Federica Grassi
  • Susanna Esposito
Nutrients (2023) 15 (10): 2341.
Evaluation of a protocol for rifaximin discontinuation in critically ill patients with liver disease receiving broad-spectrum antibiotic therapy
  • Jessica A Ward
  • Jason Yerke
  • Mollie Lumpkin
  • Aanchal Kapoor
  • Christina C Lindenmeyer
  • Stephanie Bass
World Journal of Hepatology (2023) 15 (11): 1226.
Spectrophotometric and biological studies for the interaction of rifaximin with Co, Cu, Fe and vitamin C
  • A. S. El-Kholany
  • H. A. Hafith
  • N. M. Gaber
Journal of Physics: Conference Series (2022) 2305 (1): 012039.
Long-Term Effects of Rifaximin on Patients with Hepatic Encephalopathy: Its Possible Effects on the Improvement in the Blood Ammonia Concentration Levels, Hepatic Spare Ability and Refractory Ascites
  • Keiji Yokoyama
  • Hiromi Fukuda
  • Ryo Yamauchi
  • Masashi Higashi
  • Takashi Miyayama
  • Tomotaka Higashi
  • Yotaro Uchida
  • Kumiko Shibata
  • Naoaki Tsuchiya
  • Atsushi Fukunaga
  • Kaoru Umeda
  • Kazuhide Takata
  • Takashi Tanaka
  • Satoshi Shakado
  • Shotaro Sakisaka
  • Fumihito Hirai
Medicina (2022) 58 (9): 1276.
Irritable Bowel Syndrome in Pregnancy
  • Sarvee Moosavi
  • Mark Pimentel
  • Melissa S. Wong
  • Ali Rezaie
American Journal of Gastroenterology (2021) 116 (3): 480.
Rifaximin: unique selective antibiotic for the treatment of gastrointestinal diseases
  • E. Yu. Plotnikova
Meditsinskiy sovet = Medical Council (2021) (5): 167.
Microbiome therapeutics for hepatic encephalopathy
  • Patricia P. Bloom
  • Elliot B. Tapper
  • Vincent B. Young
  • Anna S. Lok
Journal of Hepatology (2021) 75 (6): 1452.
Targeting the Gut Microbiota to Relieve the Symptoms of Irritable Bowel Syndrome
  • Tomasz Wollny
  • Tamara Daniluk
  • Ewelina Piktel
  • Urszula Wnorowska
  • Anna Bukłaha
  • Katarzyna Głuszek
  • Bonita Durnaś
  • Robert Bucki
Pathogens (2021) 10 (12): 1545.
Natural and synthetic antimicrobials reduce adherence of enteroaggregative and enterohemorrhagic Escherichia coli to epithelial cells
  • Yaraymi Ortiz
  • Alam García-Heredia
  • Angel Merino-Mascorro
  • Santos García
  • Luisa Solís-Soto
  • Norma Heredia
  • Yung-Fu Chang
PLOS ONE (2021) 16 (5): e0251096.
Review of Rifaximin: A Summary of the Current Evidence and Benefits Beyond Licensed Use
  • Rooshi Nathwani
  • Benjamin Mullish
  • David Kockerling
  • Alexander Cole
  • Nowlan Selvapatt
  • Ameet Dhar
European Medical Journal 94.
Randomized, Placebo-Controlled Trial of Rifaximin Therapy for Lowering Gut-Derived Cardiovascular Toxins and Inflammation in CKD
  • Cassandra Kimber
  • Shiqin Zhang
  • Cassandra Johnson
  • Raymond E. West
  • Alexander J. Prokopienko
  • Jonathan D. Mahnken
  • Alan S. Yu
  • Andrew N. Hoofnagle
  • Diana Ir
  • Charles E. Robertson
  • Makoto Miyazaki
  • Michel Chonchol
  • Anna Jovanovich
  • Bryan Kestenbaum
  • Daniel N. Frank
  • Thomas D. Nolin
  • Jason R. Stubbs
Kidney360 (2020) 1 (11): 1206.
Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma
  • Stephan Spahn
  • Daniel Roessler
  • Radu Pompilia
  • Gisela Gabernet
  • Beryl Primrose Gladstone
  • Marius Horger
  • Saskia Biskup
  • Magdalena Feldhahn
  • Sven Nahnsen
  • Franz J. Hilke
  • Bernhard Scheiner
  • Jean-François Dufour
  • Enrico N. De Toni
  • Matthias Pinter
  • Nisar P. Malek
  • Michael Bitzer
Cancers (2020) 12 (12): 3830.
Efficacy of and Resistance to Rifaximin-based Quadruple Therapy in Helicobacter pylori Eradication
  • Hyun Soo Kim
  • Hyuk Yoon
  • Dong Woo Shin
  • Dong Jun Oh
  • Mingu Kwon
  • Yoon Jin Choi
  • Cheol Min Shin
  • Young Soo Park
  • Nayoung Kim
  • Dong Ho Lee
The Korean Journal of Helicobacter and Upper Gastrointestinal Research (2020) 20 (3): 218.
Rifaximin-Alpha and Other Crystalline Forms of Rifaximin: Are There Any Differences?
  • S. K. Zyryanov
  • E. A. Baybulatova
Antibiotics and Chemotherapy (2020) 65 (7-8): 52.
Efficacy and safety of rifaximin treatment in Japanese patients with hepatic encephalopathy
  • Mitsuhiko Shibasaki
  • Takeshi Hatanaka
  • Yasushi Shimada
  • Tamon Nagashima
  • Masashi Namikawa
  • Shuichi Saito
  • Kenichi Hosonuma
  • Atsushi Naganuma
  • Daichi Takizawa
  • Hirotaka Arai
  • Takashi Kosone
  • Hitoshi Takagi
  • Ken Sato
  • Satoru Kakizaki
  • Toshio Uraoka
Kanzo (2020) 61 (1): 1.
Chronic pancreatitis with IBS-like syndrome: approach to therapy
  • I. V. Kozlova
  • A. P. Bykova
  • M. A. Osadchuk
Terapevticheskii arkhiv (2020) 92 (2): 61.
Monoclonal antibody production and the development of a quantitative time-resolved fluoroimmunoassay for rifaximin in milk
  • Licai Ma
  • Zhanhui Wang
  • Hebing Liu
  • Congming Wu
  • Yafang Ding
  • Kai Wen
Food and Agricultural Immunology (2019) 30 (1): 1135.
Specific Interactions between Rifamycin Antibiotics and Water Influencing Ability To Overcome Natural Cell Barriers and the Range of Antibacterial Potency
  • Krystian Pyta
  • Anna Janas
  • Natalia Skrzypczak
  • Wojciech Schilf
  • Barbara Wicher
  • Maria Gdaniec
  • Franz Bartl
  • Piotr Przybylski
ACS Infectious Diseases (2019) 5 (10): 1754.
Improving solubility and storage stability of rifaximin via solid-state solvation with Transcutol®
  • F. Grepioni
  • D. Braga
  • L. Chelazzi
  • O. Shemchuk
  • P. Maffei
  • A. Sforzini
  • G. C. Viscomi
CrystEngComm (2019) 21 (35): 5278.
Irritable Bowel Syndrome
  • Nuha Alammar
  • Ellen Stein
Medical Clinics of North America (2019) 103 (1): 137.
Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome
  • Anthony A. Fodor
  • Mark Pimentel
  • William D. Chey
  • Anthony Lembo
  • Pamela L. Golden
  • Robert J. Israel
  • Ian M. Carroll
Gut Microbes (2019) 10 (1): 22.
Transcriptional and Translational Inhibitors Block SOS Response and Shiga Toxin Expression in Enterohemorrhagic Escherichia coli
  • Michael Berger
  • Iqbal Aijaz
  • Petya Berger
  • Ulrich Dobrindt
  • Gerald Koudelka
Scientific Reports (2019) 9 (1)
Norfloxacin is more effective than Rifaximin in avoiding bacterial translocation in an animal model of cirrhosis
  • Isabel Gómez‐Hurtado
  • Paula Gimenez
  • Irma García
  • Pedro Zapater
  • Rubén Francés
  • José M. González‐Navajas
  • Chaysavanh Manichanh
  • José M. Ramos
  • Pablo Bellot
  • Francisco Guarner
  • José Such
Liver International (2018) 38 (2): 295.
Rifaximin in non‐alcoholic steatohepatitis: An open‐label pilot study
  • Jeremy F.L. Cobbold
  • Stephen Atkinson
  • Julian R. Marchesi
  • Ann Smith
  • Sann N. Wai
  • Julie Stove
  • Fariba Shojaee‐Moradie
  • Nicola Jackson
  • A. Margot Umpleby
  • Julie Fitzpatrick
  • E. Louise Thomas
  • Jimmy D. Bell
  • Elaine Holmes
  • Simon D. Taylor‐Robinson
  • Robert D. Goldin
  • Michael S. Yee
  • Quentin M. Anstee
  • Mark R. Thursz
Hepatology Research (2018) 48 (1): 69.
Gut dysbiosis and irritable bowel syndrome: The potential role of probiotics
  • Nicola Principi
  • Rita Cozzali
  • Edoardo Farinelli
  • Andrea Brusaferro
  • Susanna Esposito
Journal of Infection (2018) 76 (2): 111.
Efficacy and safety of rifaximin in Japanese patients with hepatic encephalopathy: A phase II/III, multicenter, randomized, evaluator‐blinded, active‐controlled trial and a phase III, multicenter, open trial
  • Kazuyuki Suzuki
  • Ryujin Endo
  • Yasuhiro Takikawa
  • Fuminori Moriyasu
  • Yutaka Aoyagi
  • Hisataka Moriwaki
  • Shuji Terai
  • Isao Sakaida
  • Yoshiyuki Sakai
  • Shuhei Nishiguchi
  • Toru Ishikawa
  • Hitoshi Takagi
  • Atsushi Naganuma
  • Takuya Genda
  • Takafumi Ichida
  • Koichi Takaguchi
  • Katsuhiko Miyazawa
  • Kiwamu Okita
Hepatology Research (2018) 48 (6): 411.
Primary Prophylaxis to Prevent the Development of Hepatic Encephalopathy in Cirrhotic Patients with Acute Variceal Bleeding
  • Fátima Higuera-de-la-Tijera
  • Alfredo I. Servín-Caamaño
  • Francisco Salas-Gordillo
  • José L. Pérez-Hernández
  • Juan M. Abdo-Francis
  • Jaime Camacho-Aguilera
  • Sai N. Alla
  • Fiacro Jiménez-Ponce
Canadian Journal of Gastroenterology and Hepatology (2018) 2018: 1.
Rifaximin has minor effects on bacterial composition, inflammation, and bacterial translocation in cirrhosis: A randomized trial
  • Nina Kimer
  • Julie S Pedersen
  • Juliette Tavenier
  • Jeffrey E Christensen
  • Troels M Busk
  • Lise Hobolth
  • Aleksander Krag
  • Waleed Abu Al‐Soud
  • Martin S Mortensen
  • Søren J Sørensen
  • Søren Møller
  • Flemming Bendtsen
Journal of Gastroenterology and Hepatology (2018) 33 (1): 307.
Rifaximin for the prevention of spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis: a systematic review and meta-analysis
  • Faisal Kamal
  • Muhammad Ali Khan
  • Zubair Khan
  • George Cholankeril
  • Tariq A. Hammad
  • Wade M. Lee
  • Aijaz Ahmed
  • Bradford Waters
  • Colin W. Howden
  • Satheesh Nair
  • Sanjaya K. Satapathy
European Journal of Gastroenterology & Hepatology (2017) 29 (10): 1109.
Systematic review with meta‐analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth
  • L. Gatta
  • C. Scarpignato
Alimentary Pharmacology & Therapeutics (2017) 45 (5): 604.
The effect of sub-inhibitory concentrations of rifaximin on urease production and on other virulence factors expressed by Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa and Staphylococcus aureus
  • Annalisa Ricci
  • Erika Coppo
  • Ramona Barbieri
  • Eugenio A. Debbia
  • Anna Marchese
Journal of Chemotherapy (2017) 29 (2): 67.
Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity
  • M. Pimentel
  • B. D. Cash
  • A. Lembo
  • R. A. Wolf
  • R. J. Israel
  • P. Schoenfeld
Digestive Diseases and Sciences (2017) 62 (9): 2455.
Susceptibilidad a la rifaximina y otros antimicrobianos de bacterias aisladas en pacientes con infecciones gastrointestinales agudas en el sureste de México
  • O. Novoa-Farias
  • A.C. Frati-Munari
  • M.A. Peredo
  • S. Flores-Juárez
  • O. Novoa-García
  • J. Galicia-Tapia
  • C.E. Romero-Carpio
Revista de Gastroenterología de México (2017) 82 (3): 226.
Susceptibility to rifaximin and other antimicrobials of bacteria isolated in patients with acute gastrointestinal infections in Southeast Mexico
  • O. Novoa-Farias
  • A.C. Frati-Munari
  • M.A. Peredo
  • S. Flores-Juárez
  • O. Novoa-García
  • J. Galicia-Tapia
  • C.E. Romero-Carpio
Revista de Gastroenterología de México (English Edition) (2017) 82 (3): 226.
Review of Rifaximin: Latest Treatment Frontier for Irritable Bowel Syndrome Mechanism of Action and Clinical Profile
  • Kamesh Gupta
  • Harparam Singh Ghuman
  • Shivani Vijay Handa
Clinical Medicine Insights: Gastroenterology (2017) 10: 117955221772890.
Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity
  • Kosuke Kaji
  • Hiroaki Takaya
  • Soichiro Saikawa
  • Masanori Furukawa
  • Shinya Sato
  • Hideto Kawaratani
  • Mitsuteru Kitade
  • Kei Moriya
  • Tadashi Namisaki
  • Takemi Akahane
  • Akira Mitoro
  • Hitoshi Yoshiji
World Journal of Gastroenterology (2017) 23 (47): 8355.
Lactulose reduces bacterial DNA translocation, which worsens neurocognitive shape in cirrhotic patients with minimal hepatic encephalopathy
  • Alba Moratalla
  • Javier Ampuero
  • Pablo Bellot
  • Rocío Gallego‐Durán
  • Pedro Zapater
  • Manuela Roger
  • Blanca Figueruela
  • Belén Martínez‐Moreno
  • José M. González‐Navajas
  • José Such
  • Manuel Romero‐Gómez
  • Rubén Francés
Liver International (2017) 37 (2): 212.
Small bowel protection against NSAID-injury in rats: Effect of rifaximin, a poorly absorbed, GI targeted, antibiotic
  • Matteo Fornai
  • Luca Antonioli
  • Carolina Pellegrini
  • Rocchina Colucci
  • Deborah Sacco
  • Erika Tirotta
  • Gianfranco Natale
  • Alessia Bartalucci
  • Marina Flaibani
  • Cecilia Renzulli
  • Emilia Ghelardi
  • Corrado Blandizzi
  • Carmelo Scarpignato
Pharmacological Research (2016) 104: 186.
Bacterial Transcription as a Target for Antibacterial Drug Development
  • Cong Ma
  • Xiao Yang
  • Peter J. Lewis
Microbiology and Molecular Biology Reviews (2016) 80 (1): 139.
Susceptibility to rifaximin and other antimicrobial agents of bacteria isolated from acute gastrointestinal infections in Mexico
  • O. Novoa-Farías
  • A.C. Frati-Munari
  • M.A. Peredo
  • S. Flores-Juárez
  • O. Novoa-García
  • J. Galicia-Tapia
  • C.E. Romero-Carpio
Revista de Gastroenterología de México (English Edition) (2016) 81 (1): 3.
Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea
  • M. Pimentel
Alimentary Pharmacology & Therapeutics (2016) 43 (S1): 37.
  • Online ISSN 1421-9794
  • Print ISSN 0009-3157
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal